Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy

Epilepsia

Volumn 44, Issue 11, 2003, Pages 1388-1396

  Sisodiya, Sanjay M ^a,d   Martinian, Lillian ^a   Scheffer, George L ^c   Van der Valk, Paul ^c   Cross, J Helen ^b   Scheper, Rik J ^c   Harding, Brian N ^b   Thom, Maria ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drug; Breast cancer resistance protein; Dysembryoplastic neuroepithelial tumor; Focal cortical dysplasia; Hippocampal sclerosis; Major vault protein

Indexed keywords

ABC TRANSPORTER; ANTICONVULSIVE AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; FELBAMATE; GLYCOPROTEIN P; LAMOTRIGINE; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; CORTICAL DYSPLASIA; EPILEPSY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; NEUROEPITHELIOMA; PRIORITY JOURNAL;

ANTICONVULSANTS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN NEOPLASMS; CAPILLARIES; CEREBRAL CORTEX; DRUG RESISTANCE, MULTIPLE; ENDOTHELIUM, VASCULAR; EPILEPSY; HIPPOCAMPUS; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; NEOPLASMS, NEUROEPITHELIAL; NEURONS; PHENOTYPE; REFERENCE VALUES; SCLEROSIS; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0242490855     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.21803.x     Document Type: Article

References (47)

1. Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-16.
2. Casetta I, Granieri E, Monetti VC, et al. Early predictors of intractability in childhood epilepsy: a community-based case-control study in Copparo, Italy. Acta Neurol Scand 1999;99:329-33.
3. Gelisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001;70:240-3.
4. MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48:833-41.
5. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
6. Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21:731-4.
7. Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10:3437-41.
8. Sisodiya SM, Lin W-R, Squier MV, et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:42-3.
9. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-6.
10. Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125:22-31.
11. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003 (in press) [epub ahead of print]
12. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22:5833-9.
13. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
14. Kwan P, Sills G, Meldrum BS, et al. P-glycoprotein and multidrug resistance (MDR) gene expression in epilepsy. Epilepsia 2000;41(suppl 7):161.
15. Huai-Yun H, Secrest DT, Mark KS, et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 1998;243:816-20.
16. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002;327:173-6.
17. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12:3557-60.
18. Siddiqui A, Kerb R, Weale M, et al. Association of multidrug resistance in epilepsy with a polymorphism in ABCBI. N Engl J Med 2003;348:1442-8.
19. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
20. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
21. Lage H, Dietel M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000;1:169-75.
22. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-21.
23. Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001;288:827-32.
24. Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7:145-52.
25. Volk EL, Farley KM, Wu Y, et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-40.
26. Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-9.
27. Steinbach D, Sell W, Voigt A, et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002;16:1443-7.
28. Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12:550-6.
29. Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1:578-82.
30. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475-9.
31. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148:877-87.
32. Schroeijers AB, Scheffer GL, Flens MJ, et al. Immunohistochemical detection of the human major vault protein LRP with two monoclonal antibodies in formalin-fixed, paraffin-embedded tissues. Am J Pathol 1998;152:373-8.
33. Schroeijers AB, Scheffer GL, Reurs AW, et al. Detection of the Mr 110, 000 lung resistance-related protein LRP/MVP with monoclonal antibodies. J Histochem Cytochem 2001;49:1379-85.
34. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
35. Cooray HC, Blackmore CG, Maskell L, et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13:2059-63.
36. Berger W, Spiegl-Kreinecker S, Buchroithner J, et al. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 2001;94:377-82.
37. Hu Y, Stephen AG, Cao J, et al. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. Int J Cancer 2002;97:149-56.
38. Siva AC, Raval-Fernandes S, Stephen AG, et al. Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 2001;92:195-202.
39. Kickhoefer VA, Rajavel KS, Scheffer GL, et al. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273:8971-4.
40. Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91:1647-53.
41. Cheng SH, Lam W, Lee AS, et al. Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 2000;164:134-42.
42. Schroeijers AB, Siva AC, Scheffer GL, et al. The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. Cancer Res 2000;60:1104-10.
43. Mossink MH, van Zon A, Franzel-Luiten E, et al. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 2002;62:7298-304.
44. Filipits M, Stranzl T, Pohl G, et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000;14:68-76.
45. Kickhoefer VA, Siva AC, Kedersha NL, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999;146:917-28.
46. Herrmann C, Golkaramnay E, Inman E, et al. Recombinant major vault protein is targeted to neuritic tips of PC12 cells. J Cell Biol 1999;144:1163-72.
47. Li JY, Volknandt W, Dahlstrom A, et al. Axonal transport of ribonucleoprotein particles (vaults). Neuroscience 1999;91:1055-65.